Saturday 17 October 2026
Export ACGN’s income statement to Excel — free account
Aceragen, Inc.
ACGN Healthcare Biotechnology
Aceragen, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $4.9 million. Operating cash flow growth for five consecutive years.
Follow ACGN
| Older periods | Jun '22 | Sep '22 | Dec '22 | Mar '23 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(49.57%) | (43.59%) | (113.18%) | (169.66%) | |
| (41.25%) | (16.41%) | (34.36%) | (75.58%) | ||
ROIC |
0.00% | (62.09%) | (64.66%) | (135.35%) | |
Return on Tangible Assets |
(69.90%) | (108.03%) | 657.47% | 335.83% | |
Average Days of Receivables |
— | 411.75 | 239.65 | 91.58 | |
Free Cash Flow per Share |
(5.41) | (4.90) | (7.52) | (4.00) | |
Free Cash Flow |
(16.84) | (15.34) | (24.49) | (29.78) | |
| Other line items | |||||
Cash ROIC |
(36.92%) | (19.99%) | (48.05%) | (120.73%) | |
Accounts Receivable Turnover |
— | 1.74 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.11 | 0.00 | 0.00 | 0.00 | |
Inventory Turnover |
0.00 | 0.00 | — | — | |
Average Days of Payables |
2,843.16 | 154,235.31 | 0.00 | 0.00 | |
Days of Inventory on Hand |
0.00 | 0.00 | — | — | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 463.18% | 190.17% | 175.36% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 536.59% | 190.56% | 167.82% | |
Share Based Compensation of Revenue |
0.00% | 118.61% | 34.14% | 32.73% | |
Interest Coverage |
(4,909.00) | (203.50) | — | — | |
Operating CF/Net income |
1.15 | 1.31 | 1.05 | 0.73 | |
Depreciation/Fixed assets |
1.36 | 1.45 | 2.14 | 2,771.25 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.56 | 1.97 | 1.18 | |
Operating CF per Share |
(5.41) | (4.90) | (7.52) | (4.00) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
— | 0.00 | 0.00 | 0.00 |
Columns are period end dates